Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 19;77(10):690-696.
doi: 10.1136/jcp-2023-208856.

PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study

Federica Miglietta  1   2 , Valentina Carraro  3 , Ottavia Amato  4   2 , Gaia Griguolo  4   2 , Michele Bottosso  4   2 , Giada Munari  5 , Giovanni Zarrilli  6 , Marcello Lo Mele  7 , Caterina Barbieri  4   2 , Angelo Paolo Dei Tos  6 , Valentina Guarneri  4   2 , Maria Vittoria Dieci #  4   2 , Matteo Fassan #  5   6
Affiliations

PI3K/PTEN/mTOR pathway dynamic tracking and prognostic value in HR+/HER2- BC patients with residual disease after neoadjuvant chemotherapy: a cohort study

Federica Miglietta et al. J Clin Pathol. .

Abstract

Aims: Hormone receptor-positive (HR)+/HER2- breast cancer (BC) is highly heterogeneous, with PI3K/PTEN/mTOR pathway alterations emerging as possible players within this complexity. We longitudinally tracked PI3K/PTEN/mTOR pathway dynamics from baseline biopsy to residual disease (RD)-and to metastases in case of relapse-in HR+/HER2- BC patients receiving neoadjuvant chemotherapy (NACT).

Methods: HR+/HER2- BC patients with RD after NACT were identified. We assessed PIK3CA mutational, Pten-loss and phosphorylation levels of mTOR and its substrates (p70S6K and 4EBP1) on baseline biopsies and matched RD samples; in case of disease relapse, we also assessed PIK3CA mutational status on metastatic samples. Recurrence-free survival (RFS) was adopted as endpoint.

Results: 92 patient were included. The conversion rate of PIK3CA mutational status was 12.8%; 1 patient acquired PIK3CA mutation at relapse; the rate of Pten conversion was 33.3%; mTOR phosphorylation levels significantly increased from baseline biopsy to RD, while its substrates significantly decreased. Baseline phosphorylated-mTOR significantly predicted poorer RFS in patients with PIK3CA wild-type status; baseline phosphorylated-70S6K was positively associated with RFS.

Conclusions: We observed that PI3K/PTEN/mTOR pathway is highly dynamic under NACT exposure and the assessment of PIK3CA mutations may capture only a small fraction of such complexity. In this context, mTOR activation trough alternative pathways with respect to PIK3CA signalling may have a crucial role in shaping the molecular landscape of HR+/HER2- BC with RD after NACT. It is imperative to further elucidate the role of PIK3CA and mTOR-dependent pathways in shaping chemoresistance and endocrine resistance in high-risk HR+/HER2- early/locally advanced BC patients.

Keywords: BREAST CANCER; IMMUNOHISTOCHEMISTRY; NEOPLASMS.

PubMed Disclaimer

Conflict of interest statement

Competing interests: FM received personal fee from Roche, Novartis and Gilead, outside the submitted manuscript. GG reports personal fee from Novartis, Eli Lilly, and Gilead outside the submitted work. VG reports personal fees for advisory board membership from Eisai, Eli Lilly, Exact Sciences, Gilead, Merck Serono, MSD, Novartis, Olema Oncology and Sanofi; personal fees as an invited speaker from Amgen, Eli Lilly, GSK, Astra Zeneca, Novartis; personal fees for expert testimony from Eli Lilly; institutional funding as a local PI from AstraZeneca, BMS, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Merck, MSD, Nerviano, Novartis, Roche and Synton Biopharmaceutical. MF has been involved in consulting/advisory roles in Astellas Pharma, Tesaro, MSD, Pierre Fabre, Astra Zeneca, Incyte, GlaxoSmithKline, Diaceutics and Roche, received research funding from Astellas Pharma, QED Therapeutics, and Macrophage Pharma and is supported by grants from the Italian Health Ministry/Veneto region research program NET-2016-02363853 and AIRC 5 per mille 2019 (ID. 22759 programme). MVD reports personal fees from Eli Lilly, MSD, Exact Sciences, Novartis, Pfizer, Seagen, outside the submitted work.

Figures

Figure 1
Figure 1. PIK3CA mutational status evolution from baseline biopsy to RD to metastatic tissue (in case of disease relpase). RD, residual disease.
Figure 2
Figure 2. 70S6K phosphorylation level dynamics according to PIK3CA mutational status evolution from baseline biopsy to RD. RD, residual disease WT, wild-type.
Figure 3
Figure 3. Kaplan-Meier curves of RFS according to mTOR phosphorylation status. (A) Overall; (B) PIK3CA-wt cohort. RFS, recurrence-free survival.
Figure 4
Figure 4. Kaplan-Meier curves of RFS according to 70S6K phosphorylation status. RFS, recurrence-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. WHO Breast cancer. 2020. https://www.who.int/news-room/fact-sheets/detail/breast-cancer#:~:text=I... Available.
    1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70. doi: 10.1038/nature11412. - DOI - PMC - PubMed
    1. Fusco N, Malapelle U, Fassan M, et al. Pik3Ca mutations as a molecular target for hormone receptor-positive, Her2-negative metastatic breast cancer. Front Oncol. 2021;11:644737. doi: 10.3389/fonc.2021.644737. - DOI - PMC - PubMed
    1. Fillbrunn M, Signorovitch J, André F, et al. Pik3Ca Mutation status, progression and survival in advanced HR + /Her2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022;22:1002. doi: 10.1186/s12885-022-10078-5. - DOI - PMC - PubMed

MeSH terms